Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas.
Fiedler W, Cresta S, Schulze-Bergkamen H, De Dosso S, Weidmann J, Tessari A, Baumeister H, Danielczyk A, Dietrich B, Goletz S, Zurlo A, Salzberg M, Sessa C, Gianni L. Fiedler W, et al. Among authors: gianni l. ESMO Open. 2018 Feb 1;3(2):e000303. doi: 10.1136/esmoopen-2017-000303. eCollection 2018. ESMO Open. 2018. PMID: 29464112 Free PMC article.
Anthracyclines.
Gianni L, Grasselli G, Cresta S, Locatelli A, Viganò L, Minotti G. Gianni L, et al. Cancer Chemother Biol Response Modif. 2002;20:59-69. Cancer Chemother Biol Response Modif. 2002. PMID: 12703200 Review. No abstract available.
Cardiotoxic effects of anthracycline-taxane combinations.
Perotti A, Cresta S, Grasselli G, Capri G, Minotti G, Gianni L. Perotti A, et al. Among authors: gianni l. Expert Opin Drug Saf. 2003 Jan;2(1):59-71. doi: 10.1517/14740338.2.1.59. Expert Opin Drug Saf. 2003. PMID: 12904125 Review.
Anthracyclines.
Gianni L, Grasselli G, Cresta S, Locatelli A, Viganò L, Minotti G. Gianni L, et al. Cancer Chemother Biol Response Modif. 2003;21:29-40. Cancer Chemother Biol Response Modif. 2003. PMID: 15338739 Review. No abstract available.
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Perotti A, Locatelli A, Sessa C, Hess D, Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L. Perotti A, et al. Among authors: gianni l. J Clin Oncol. 2010 Oct 20;28(30):4554-61. doi: 10.1200/JCO.2009.27.5867. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855840 Clinical Trial.
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.
Sessa C, Del Conte G, Christinat A, Cresta S, Perotti A, Gallerani E, Lardelli P, Kahatt C, Alfaro V, Iglesias JL, Fernández-Teruel C, Gianni L. Sessa C, et al. Among authors: gianni l. Invest New Drugs. 2013 Oct;31(5):1236-43. doi: 10.1007/s10637-013-9942-y. Epub 2013 Mar 7. Invest New Drugs. 2013. PMID: 23467812 Clinical Trial.
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.
Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A, Goeminne JC, Hersberger V, Baselga J. Gianni L, et al. J Clin Oncol. 2010 Mar 1;28(7):1131-7. doi: 10.1200/JCO.2009.24.1661. Epub 2010 Feb 1. J Clin Oncol. 2010. PMID: 20124183 Free PMC article. Clinical Trial.
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Bahleda R, Sessa C, Del Conte G, Gianni L, Capri G, Varga A, Oprea C, Daglish B, Hospitel M, Soria JC. Bahleda R, et al. Among authors: gianni l. Invest New Drugs. 2014 Dec;32(6):1188-96. doi: 10.1007/s10637-014-0119-0. Epub 2014 Jun 6. Invest New Drugs. 2014. PMID: 24898305 Clinical Trial.
386 results